Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linsey Porter

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Seminars in Cancer Biology|September 9, 2020
SOX2 and squamous cancersLinsey Porter, Frank McCaughan
Thorax|August 6, 2010
Live and let die: is neutrophil apoptosis defective in severe asthma?Helen Parfrey, Neda Farahi, Linsey Porter, et al.
Frontiers in Immunology|July 18, 2018
Metabolic Profiling of Human EosinophilsLinsey Porter, Nicole Toepfner, Kathleen R Bashant, et al.
Expert Review of Respiratory Medicine|January 28, 2014
Biomarkers of eosinophilic inflammation in asthmaChrystalla Loutsios, Neda Farahi, Linsey Porter, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 3, 2014
Measurement of eosinophil kinetics in healthy volunteersNeda Farahi, Chrystalla Loutsios, Rosalind P Simmonds, et al.
Data in Brief|June 2, 2017
In-depth immunophenotyping data of IL-6R on the human peripheral regulatory T cell (Treg) compartmentRicardo C Ferreira, Daniel B Rainbow, Arcadio Rubio García, et al.
Clinical Immunology (Orlando, Fla.)|March 13, 2017
Human IL-6R<sup>hi</sup>TIGIT<sup>-</sup> CD4<sup>+</sup>CD127<sup>low</sup>CD25<sup>+</sup> T cells display potent in vitro suppressive capacity and a distinct Th17 profileRicardo C Ferreira, Daniel B Rainbow, Arcadio Rubio García, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 8, 2010
Hypoxia selectively inhibits respiratory burst activity and killing of Staphylococcus aureus in human neutrophilsNaomi N McGovern, Andrew S Cowburn, Linsey Porter, et al.
Thorax|September 2, 2016
Hypoxia upregulates neutrophil degranulation and potential for tissue injuryKim Hoenderdos, Katharine M Lodge, Robert A Hirst, et al.
JCI Insight|October 5, 2018
The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetesEleonora Seelig, James Howlett, Linsey Porter, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Seminars in Cancer Biology|September 9, 2020
SOX2 and squamous cancersLinsey Porter, Frank McCaughan
Thorax|August 6, 2010
Live and let die: is neutrophil apoptosis defective in severe asthma?Helen Parfrey, Neda Farahi, Linsey Porter, et al.
Frontiers in Immunology|July 18, 2018
Metabolic Profiling of Human EosinophilsLinsey Porter, Nicole Toepfner, Kathleen R Bashant, et al.
Expert Review of Respiratory Medicine|January 28, 2014
Biomarkers of eosinophilic inflammation in asthmaChrystalla Loutsios, Neda Farahi, Linsey Porter, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 3, 2014
Measurement of eosinophil kinetics in healthy volunteersNeda Farahi, Chrystalla Loutsios, Rosalind P Simmonds, et al.
Data in Brief|June 2, 2017
In-depth immunophenotyping data of IL-6R on the human peripheral regulatory T cell (Treg) compartmentRicardo C Ferreira, Daniel B Rainbow, Arcadio Rubio García, et al.
Clinical Immunology (Orlando, Fla.)|March 13, 2017
Human IL-6R<sup>hi</sup>TIGIT<sup>-</sup> CD4<sup>+</sup>CD127<sup>low</sup>CD25<sup>+</sup> T cells display potent in vitro suppressive capacity and a distinct Th17 profileRicardo C Ferreira, Daniel B Rainbow, Arcadio Rubio García, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 8, 2010
Hypoxia selectively inhibits respiratory burst activity and killing of Staphylococcus aureus in human neutrophilsNaomi N McGovern, Andrew S Cowburn, Linsey Porter, et al.
Thorax|September 2, 2016
Hypoxia upregulates neutrophil degranulation and potential for tissue injuryKim Hoenderdos, Katharine M Lodge, Robert A Hirst, et al.
JCI Insight|October 5, 2018
The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetesEleonora Seelig, James Howlett, Linsey Porter, et al.
Pageof 2